Inundated by demand, Gilead halts individual emergency access to experimental Covid-19 drug
Slammed with a tidal wave of compassionate use requests, Gilead says it will have to put a halt to meeting individual appeals for their coronavirus drug remdesivir while they focus on wrapping a clinical trial to see if it works.
In recent days, the anti-malarial drug chloroquine and similar drug hydroxychloroquine have soaked up the spotlight as potential “game-changers” to combat the coronavirus scourge that has enveloped the globe. But Gilead’s antiviral remdesivir was one of the first to be touted as a potential therapy and is also one of the furthest along the path towards approval.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.